Review of teriflunomide and its potential in the treatment of multiple sclerosis
Clemens Warnke1, Gerd Meyer zu Hörste1, Hans-Peter Hartung1, Olaf Stüve2,3,4, Bernd C Kieseier11Department of Neurology, Heinrich-Heine-University Düsseldorf, Germany; 2Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA; 3Dep...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-05-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Online Access: | http://www.dovepress.com/review-of-teriflunomide-and-its-potential-in-the-treatment-of-multiple-a3170 |
| Summary: | Clemens Warnke1, Gerd Meyer zu Hörste1, Hans-Peter Hartung1, Olaf Stüve2,3,4, Bernd C Kieseier11Department of Neurology, Heinrich-Heine-University Düsseldorf, Germany; 2Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA; 3Department of Neurology; 4Department of immunology, University of Texas Southwestern Medical Center at Dallas, TX, USAAbstract: In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less severely affected MS patients are a major focus of drug development. These agents are currently investigated in phase III clinical trials and some of them are characterized by a favorable safety profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed.Keywords: teriflunomide, multiple sclerosis, immunosuppressant, oral drugs |
|---|---|
| ISSN: | 1176-6328 1178-2021 |